Research gaps in defining the biological link between HIV risk and hormonal contraception

American Journal of Reproductive Immunology

Volumn 72, Issue 2, 2014, Pages 228-235

  Murphy, Kerry ^a   Irvin, Susan C ^a   Herold, Betsy C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Depo Provera; Female genital tract; HIV; Hormonal contraception; Mucosal immunity

Indexed keywords

MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT;

ADAPTIVE IMMUNITY; CELLULAR IMMUNITY; GENITAL HERPES; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; INFECTION RISK; INNATE IMMUNITY; MICROBIOME; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; ANIMAL; CELL JUNCTION; CONTRACEPTION; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MICROFLORA; MUCOSA; MUCOSAL IMMUNITY; PATHOLOGY; PERMEABILITY; RISK; TRANSMISSION; VAGINA; VIROLOGY;

ANIMALS; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HERPES GENITALIS; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; INTERCELLULAR JUNCTIONS; MEDROXYPROGESTERONE ACETATE; MICROBIOTA; MUCOUS MEMBRANE; PERMEABILITY; RISK; VAGINA;

EID: 84904291192     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12209     Document Type: Review

References (71)

1. Hel Z, Stringer E, Mestecky J: Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection. Endocr Rev 2010; 31:79-97.
2. Phillips SJ, Curtis KM, Polis CB: Effect of hormonal contraceptive methods on HIV disease progression: a Systematic Review. AIDS 2013; 27:787-794.
3. Polis CB, Phillips SJ, Curtis KM: Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS 2013; 27:493-505.
4. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB: Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 2013; 27:105-113.
5. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, de Bruyn G, Nakku-Joloba E, Ngure K, Kiarie J, Coombs RW, Baeten JM: Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
6. Klebanoff SJ, Coombs RW: Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 1991; 174:289-292.
7. Baeten JM, Nyange PM, Richardson BA, Lavreys L, Chohan B, Martin HL, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, Kreiss JK: Hormonal contraception and risk of sexually transmitted disease acquisition: results from a prospective study. Am J Obstet Gynecol 2001; 185:380-385.
8. Cherpes TL, Melan MA, Kant JA, Cosentino LA, Meyn LA, Hillier SL: Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis 2005; 40:1422-1428.
9. Smith JS, Herrero R, Munoz N, Eluf-Neto J, Ngelangel C, Bosch FX, Ashley RL: Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines. Sex Transm Dis 2001; 28:187-194.
10. Sanders-Beer B, Babas T, Mansfield K, Golightly D, Kramer J, Bowlsbey A, Sites D, Nieves-Duran L, Lin S, Rippeon S, Donnelly G, Rhodes L, Spano YE: Depo-Provera does not alter disease progression in SIVmac-infected female Chinese rhesus macaques. AIDS Res Hum Retroviruses 2010; 26:433-443.
11. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, Mahoney CJ, Miller CJ, Claypool LE, Ho DD, Alexander NJ: Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084-1089.
12. Vishwanathan SA, Guenthner PC, Lin CY, Dobard C, Sharma S, Adams DR, Otten RA, Heneine W, Hendry RM, McNicholl JM, Kersh EN: High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011; 57:261-264.
13. Mauck CK, Callahan MM, Baker J, Arbogast K, Veazey R, Stock R, Pan Z, Morrison CS, Chen-Mok M, Archer DF, Gabelnick HL: The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 1999; 60:15-24.
14. Bahamondes L, Trevisan M, Andrade L, Marchi NM, Castro S, Diaz J, Faundes A: The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 2000; 62:23-27.
15. Miller L, Patton DL, Meier A, Thwin SS, Hooton TM, Eschenbach DA: Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal flora and epithelium. Obstet Gynecol 2000; 96:431-439.
16. Blaskewicz CD, Pudney J, Anderson DJ: Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia. Biol Reprod 2011; 85:97-104.
17. Cordeaux Y, Tattersall M, Charnock-Jones DS, Smith GC: Effects of medroxyprogesterone acetate on gene expression in myometrial explants from pregnant women. J Clin Endocrinol Metab 2010; 95:E437-447.
18. Bobardt MD, Saphire AC, Hung HC, Yu X, Van der Schueren B, Zhang Z, David G, Gallay PA: Syndecan captures, protects, and transmits HIV to T lymphocytes. Immunity 2003; 18:27-39.
19. Saphire AC, Bobardt MD, Zhang Z, David G, Gallay PA: Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol 2001; 75:9187-9200.
20. Mondor I, Ugolini S, Sattentau QJ: Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 1998; 72:3623-3634.
21. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100:587-597.
22. Keller MJ, Guzman E, Hazrati E, Kasowitz A, Cheshenko N, Wallenstein S, Cole AL, Cole AM, Profy AT, Wira CR, Hogarty K, Herold BC: PRO 2000 elicits a decline in genital tract immune mediators without compromising intrinsic antimicrobial activity. Aids 2007; 21:467-476.
23. King AE, Fleming DC, Critchley HO, Kelly RW: Differential expression of the natural antimicrobials, beta-defensins 3 and 4, in human endometrium. J Reprod Immunol 2003; 59:1-16.
24. King AE, Critchley HO, Kelly RW: Innate immune defences in the human endometrium. Reprod Biol Endocrinol 2003; 1:116.
25. Wira CR, Patel MV, Ghosh M, Mukura L, Fahey JV: Innate immunity in the human female reproductive tract: endocrine regulation of endogenous antimicrobial protection against HIV and other sexually transmitted infections. Am J Reprod Immunol 2011; 65:196-211.
26. Schumacher GFB: Humoral immune factors in the female reproductive tract and their changes during the cycle. In Immunological Aspects of Infertility and Fertility Control. D Dinsda, G Schumacher (eds). New York, Elsevier, 1980, pp 93-141.
27. Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK, Ochiel DO: Sex hormone regulation of innate immunity in the female reproductive tract: the role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol 2010; 63:544-565.
28. Sullivan DA, Richardson GS, MacLaughlin DT, Wira CR: Variations in the levels of secretory component in human uterine fluid during the menstrual cycle. J Steroid Biochem 1984; 20:509-513.
29. Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, Joseph SB, Landucci G, Supnet MJ, Ping LH, Corti D, Moldt B, Hel Z, Lanzavecchia A, Ruprecht RM, Burton DR, Mestecky J, Anderson DJ, Forthal DN: The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells. PLoS Pathog 2013; 9:e1003776.
30. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X: Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proc Natl Acad Sci U S A 2011; 108:4388-4393.
31. Li A, Felix JC, Yang W, Jain JK: Effect of mifepristone on the expression of endometrial secretory leukocyte protease inhibitor in new medroxyprogesterone acetate users. Fertil Steril 2008; 90:872-875.
32. Novak RM, Donoval BA, Graham PJ, Boksa LA, Spear G, Hershow RC, Chen HY, Landay A: Cervicovaginal levels of lactoferrin, secretory leukocyte protease inhibitor, and RANTES and the effects of coexisting vaginoses in human immunodeficiency virus (HIV)-seronegative women with a high risk of heterosexual acquisition of HIV infection. Clin Vaccine Immunol 2007; 14:1102-1107.
33. Fakioglu E, Wilson SS, Mesquita PM, Hazrati E, Cheshenko N, Blaho JA, Herold BC: Herpes simplex virus downregulates secretory leukocyte protease inhibitor: a novel immune evasion mechanism. J Virol 2008; 82:9337-9344.
34. Patel MV, Fahey JV, Rossoll RM, Wira CR: Innate immunity in the vagina (part I): estradiol inhibits HBD2 and elafin secretion by human vaginal epithelial cells. Am J Reprod Immunol 2013; 69:463-474.
35. Fleming DC, King AE, Williams AR, Critchley HO, Kelly RW: Hormonal contraception can suppress natural antimicrobial gene transcription in human endometrium. Fertil Steril 2003; 79:856-863.
36. Africander D, Louw R, Verhoog N, Noeth D, Hapgood JP: Differential regulation of endogenous pro-inflammatory cytokine genes by medroxyprogesterone acetate and norethisterone acetate in cell lines of the female genital tract. Contraception 2011; 84:423-435.
37. Mishell DR Jr: Pharmacokinetics of depot medroxyprogesterone acetate contraception. J Reprod Med 1996; 41:381-390.
38. Hughes GC, Thomas S, Li C, Kaja MK, Clark EA: Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells. J Immunol 2008; 180:2029-2033.
39. Huijbregts RP, Helton ES, Michel KG, Sabbaj S, Richter HE, Goepfert PA, Hel Z: Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms. Endocrinology 2013; 154:1282-1295.
40. Sheffield JS, Wendel GD, McIntire DD, Norgard MV: The effect of progesterone levels and pregnancy on HIV-1 coreceptor expression. Reprod Sci 2009; 16:20-31.
41. Chandra N, Thurman AR, Anderson S, Cunningham TD, Yousefieh N, Mauck C, Doncel GF: Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res Hum Retroviruses 2013; 29:592-601.
42. Prakash M, Kapembwa MS, Gotch F, Patterson S: Oral contraceptive use induces upregulation of the CCR5 chemokine receptor on CD4(+) T cells in the cervical epithelium of healthy women. J Reprod Immunol 2002; 54:117-131.
43. Meditz AL, Moreau KL, MaWhinney S, Gozansky WS, Melander K, Kohrt WM, Wierman ME, Connick E: CCR5 expression is elevated on endocervical CD4+ T cells in healthy postmenopausal women. J Acquir Immune Defic Syndr 2012; 59:221-228.
44. Hillier S: Normal vaginal flora. In Sexually Transmitted Diseases, 4th edn. K Holmes, P Sparling, W Stamm, P Piot, J Wasserheit, L Corey, M Cohen, D Watts (eds). New York, McGraw-Hill, 2008, pp 289-307.
45. Kumar N, Behera B, Sagiri SS, Pal K, Ray SS, Roy S: Bacterial vaginosis: etiology and modalities of treatment-A brief note. J Pharm Bioallied Sci 2011; 3:496-503.
46. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM, Davis CC, Ault K, Peralta L, Forney LJ: Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci USA 2011; 108(Suppl 1):4680-4687.
47. Fredricks DN, Fiedler TL, Marrazzo JM: Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353:1899-1911.
48. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS: Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22:1493-1501.
49. Mitchell C, Balkus JE, Fredricks D, Liu C, McKernan-Mullin J, Frenkel LM, Mwachari C, Luque A, Cohn SE, Cohen CR, Coombs R, Hitti J: Interaction between lactobacilli, bacterial vaginosis-associated bacteria, and HIV Type 1 RNA and DNA Genital shedding in U.S. and Kenyan women. AIDS Res Hum Retroviruses 2013; 29:13-19.
50. Mitchell C, Hitti J, Paul K, Agnew K, Cohn SE, Luque AE, Coombs R: Cervicovaginal shedding of HIV type 1 is related to genital tract inflammation independent of changes in vaginal microbiota. AIDS Res Hum Retroviruses 2011; 27:35-39.
51. Martin HL, Richardson BA, Nyange PM, Lavreys L, Hillier SL, Chohan B, Mandaliya K, Ndinya-Achola JO, Bwayo J, Kreiss J: Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis 1999; 180:1863-1868.
52. Sha BE, Zariffard MR, Wang QJ, Chen HY, Bremer J, Cohen MH, Spear GT: Female genital-tract HIV load correlates inversely with Lactobacillus species but positively with bacterial vaginosis and Mycoplasma hominis. J Infect Dis 2005; 191:25-32.
53. Van de Wijgert JH, Verwijs MC, Turner AN, Morrison CS: Hormonal contraception decreases bacterial vaginosis but oral contraception may increase candidiasis: implications for HIV transmission. AIDS 2013; 27:2141-2153.
54. Bradshaw CS, Walker J, Fairley CK, Chen MY, Tabrizi SN, Donovan B, Kaldor JM, McNamee K, Urban E, Walker S, Currie M, Birden H, Bowden F, Garland S, Pirotta M, Gurrin L, Hocking JS: Prevalent and incident bacterial vaginosis are associated with sexual and contraceptive behaviours in young Australian women. PLoS ONE 2013; 8:e57688.
55. Bradshaw CS, Vodstrcil LA, Hocking JS, Law M, Pirotta M, Garland SM, De Guingand D, Morton AN, Fairley CK: Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. Clin Infect Dis 2013; 56:777-786.
56. Chen KT, Segú M, Lumey LH, Kuhn L, Carter RJ, Bulterys M, Abrams EJ, Group NYCPACTSP: Genital herpes simplex virus infection and perinatal transmission of human immunodeficiency virus. Obstet Gynecol 2005; 106:1341-1348.
57. Drake AL, John-Stewart GC, Wald A, Mbori-Ngacha DA, Bosire R, Wamalwa DC, Lohman-Payne BL, Ashley-Morrow R, Corey L, Farquhar C: Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007; 109:403-409.
58. Schacker T, Zeh J, Hu H, Shaughnessy M, Corey L: Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718-1725.
59. Corey L: Synergistic copathogens-HIV-1 and HSV-2. N Engl J Med 2007; 356:854-856.
60. Stefanidou M, Ramos I, Mas Casullo V, Trepanier JB, Rosenbaum S, Fernandez-Sesma A, Herold BC: Herpes simplex virus 2 (HSV-2) prevents dendritic cell maturation, induces apoptosis, and triggers release of proinflammatory cytokines: potential links to HSV-HIV synergy. J Virol 2013; 87:1443-1453.
61. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L: Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886-892.
62. Linehan MM, Richman S, Krummenacher C, Eisenberg RJ, Cohen GH, Iwasaki A: In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa. J Virol 2004; 78:2530-2536.
63. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL: Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol 2003; 77:4558-4565.
64. John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, Wallenstein S, Carlucci MJ, Tuyama AC, Lu W, Klotman ME, Lehrer RI, Herold BC: Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005; 192:1731-1740.
65. Keller MJ, Madan RP, Shust G, Carpenter CA, Torres NM, Cho S, Khine H, Huang ML, Corey L, Kim M, Herold BC: Changes in the soluble mucosal immune environment during genital herpes outbreaks. J Acquir Immune Defic Syndr 2012; 61:194-202.
66. Shust GF, Cho S, Kim M, Madan RP, Guzman EM, Pollack M, Epstein J, Cohen HW, Keller MJ, Herold BC: Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol 2010; 63:110-119.
67. Venkataraman N, Cole AL, Svoboda P, Pohl J, Cole AM: Cationic polypeptides are required for anti-HIV-1 activity of human vaginal fluid. J Immunol 2005; 175:7560-7567.
68. Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, Shust G, Mesquita PM, Louissaint N, Chen J, Cohen HW, Diament EC, Lee AC, Soto-Torres L, Hendrix CW, Herold BC: A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS ONE 2011; 6:e16475.
69. Ghosh M, Fahey JV, Shen Z, Lahey T, Cu-Uvin S, Wu Z, Mayer K, Wright PF, Kappes JC, Ochsenbauer C, Wira CR: Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS ONE 2010; 5:e11366.
70. Fichorova RN, Rheinwald JG, Anderson DJ: Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical, and vaginal epithelium that maintain expression of tissue-specific differentiation proteins. Biol Reprod 1997; 57:847-855.
71. Fichorova RN, Anderson DJ: Differential expression of immunobiological mediators by immortalized human cervical and vaginal epithelial cells. Biol Reprod 1999; 60:508-514.